SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MGI Pharma MOGN New patents, anti cancer
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: bocaburgerman who wrote (1033)6/19/1998 12:02:00 PM
From: David Cathcart  Read Replies (1) of 1826
 
Winston,

Chuck Blitzer remains very confident that the Euro deal for MGI 114 will materialize. In retrospect, I should have asked him to comment on his earlier statement specifying that it would be initialized around the beginning of phase II. He did not say anything yesterday to indicate that it would not happen then. However, it seems clear that the deal has not been sealed yet. I would imagine that MGI 114 moving into phase II - in concert with the NCI sponsoring umpteen separate trials - would be very appealing to a prospective European partner. The key of course is for the two sides to agree on terms. Chuck Blitzer clearly thinks MGI 114 is worth a lot of money.

Here is a site specifying insider buying and selling of MOGN. Tom Meyer pointed it out to me yesterday and, after looking at it for a few minutes, I picked up the phone and called Chuck Blitzer. I was fortunate to catch him at a good time; he was quite open and reassuring.

biz.yahoo.com

David
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News